Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

News Conference News VIVA 2025

ENGULF Novel PE Thrombectomy Device Minimizes Blood Loss

November 07, 2025

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

News Conference News TCT 2024

PEERLESS: FlowTriever Tops Catheter-Directed Thrombolysis for Acute PE

October 29, 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

News Conference News ACC 2024

TARGET BP 1: Alcohol-Based RDN Promises Single Treatment for Resistant BP

April 16, 2024

OPTIMAL-BP Shows Harm of Too Much BP-Lowering After Stroke Thrombectomy

News Conference News ESOC 2023

OPTIMAL-BP Shows Harm of Too Much BP-Lowering After Stroke Thrombectomy

June 01, 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

News Conference News SCAI 2023

FLASH: PE Patients Show Ongoing Clinical, QoL Gains With Thrombectomy

May 21, 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

News Conference News CRT 2023

Renal Denervation in Black Patients: SYMPLICITY HTN 3 Reassures at 36 Months

Yael L. Maxwell

February 28, 2023

Lower BP Targets After Stroke Thrombectomy Don’t Seem to Help: BEST-II

News Conference News ISC 2023

Lower BP Targets After Stroke Thrombectomy Don’t Seem to Help: BEST-II

February 10, 2023

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

News Conference News ISET 2023

The PE Pipeline: Evidence Trickles in for Catheter-Based Therapies

January 23, 2023

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

News Conference News AHA 2022

SPYRAL HTN-ON MED Trial of Renal Denervation Misses Primary Endpoint

November 09, 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

News Conference News TCT 2022

SYMPLICITY HTN-3’s Late Surprise: Sustained BP Drop at 3 Years Despite Earlier Miss

Michael O'Riordan

September 19, 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

News Conference News TCT 2022

FLASH: More Data to Support Mechanical Thrombectomy in PE

September 18, 2022

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

News Conference News ESC 2021

Massive SSaSS Study Shows Switch to Salt Substitute Cuts Stroke, CVD

Michael O'Riordan

August 29, 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

News Conference News ACC 2021

Renal Denervation Lowers BP vs Sham Procedure: RADIANCE-HTN TRIO

Michael O'Riordan

May 16, 2021

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

News Conference News ACC 2019

Renal Denervation May Lower Treatment Burden, as Well as Blood Pressure: RADIANCE-HTN SOLO

Michael O'Riordan

April 01, 2019

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

News Conference News TCT 2018

RADIOSOUND-HTN Suggests Ultrasound May Be Best for Renal Denervation

September 26, 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

News Conference News TCT 2018

Prematurely Halted Pilot Study Snaps Recent Winning Streak for Renal Denervation

September 25, 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

News Conference News EuroPCR 2018

Two Sham-Controlled Renal Denervation Studies Offer Hope in Hypertension

Michael O'Riordan

May 23, 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

News Conference News EuroPCR 2018

EuroPCR 2018: Stable CAD, Functional Tests, and Renal Denervation Take Center Stage

May 17, 2018

Shorter, Lower-Dose Ultrasound-Accelerated Thrombolysis for Acute PE Keeps Early Promise: OPTALYSE PE

News Conference News ISET 2018

Shorter, Lower-Dose Ultrasound-Accelerated Thrombolysis for Acute PE Keeps Early Promise: OPTALYSE PE

February 06, 2018

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

News Conference News ACC 2017

ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More

March 10, 2017

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.